Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
Bremelanotide, Melanocortin (MC4R) agonist
A cyclic heptapeptide melanocortin (MC4R) agonist that acts centrally on sexual desire circuitry, FDA approved as Vyleesi for premenopausal HSDD.

An FDA approved peptide that works in the brain, not the bloodstream, switching on sexual desire circuitry through melanocortin receptors. A different mechanism from Viagra type drugs.
Sexual desire
Off label
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Kingsberg SA, et al.
Across the two RECONNECT trials (1,247 premenopausal women), bremelanotide significantly improved sexual desire and reduced related distress vs placebo over 24 weeks.
FDA approved (June 2019) as Vyleesi for acquired, generalized HSDD in premenopausal women, on the basis of two Phase 3 trials (RECONNECT). Off label male use: in 342 sildenafil non responders, 34% achieved adequate erections vs 9% placebo. The label explicitly states it is NOT indicated in men or to enhance performance.
Nausea (~40% on first dose, often subsides); transient blood pressure rise (~6 mmHg systolic) with heart rate decrease resolving within 12 hours; focal hyperpigmentation with repeated use.
Uncontrolled hypertension, CVD, history of stroke/MI; pregnancy; concurrent naltrexone.
FDA approved (Palatin Technologies). Gray market PT-141 is widely sold for men off label. WADA: not explicitly named, but caution advised.
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.